Friday 6 November 2026
Export EVH’s income statement to Excel — free account
Evolent Health, Inc
EVH Healthcare Health Information Services
Evolent Health, Inc’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 26.6% from fiscal 2024.
- Revenue
- +51.3%
- EPS
- +12.5%
- Free cash flow
- +179.8%
- Total debt
- −8.09%
Quarter to September 2026, against a year earlier
4.60
0.06
+1.32%
Follow EVH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 5 | 6 | 4 |
| (81.81%) | (80.15%) | (79.90%) | (83.57%) | ||
| (26.08%) | (23.55%) | (23.05%) | (23.00%) | ||
ROIC |
(21.22%) | (21.76%) | (22.06%) | (22.87%) | |
Return on Tangible Assets |
(286.98%) | (264.31%) | (256.04%) | (242.12%) | |
Average Days of Receivables |
60.28 | 60.71 | 78.17 | 68.98 | |
Free Cash Flow per Share |
0.04 | 0.01 | 0.22 | 0.32 | |
Free Cash Flow |
4.76 | 1.40 | 24.34 | 36.66 | |
Capital Expenditures |
(34.09) | (31.90) | (29.98) | (28.22) | |
| Other line items | |||||
Cash ROIC |
0.30% | 0.09% | 1.64% | 2.45% | |
Accounts Receivable Turnover |
5.18 | 5.07 | 5.19 | 5.65 | |
Accounts Payable Turnover |
18.95 | 24.96 | 32.05 | 36.22 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
14.78 | 15.25 | 8.17 | 6.93 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.20% | 15.79% | 13.92% | 12.27% | |
Share Based Compensation of Revenue |
2.12% | 2.08% | 2.05% | 1.84% | |
Interest Coverage |
(7.14) | (6.55) | (6.18) | (6.23) | |
Operating CF/Net income |
(0.07) | (0.06) | (0.11) | (0.13) | |
Depreciation/Fixed assets |
6.54 | 6.50 | 6.44 | 0.00 | |
Capex/Depreciation |
(0.06) | (0.06) | (0.06) | 0.00 | |
Revenue per Share |
16.43 | 16.88 | 18.63 | 20.72 | |
Operating CF per Share |
0.34 | 0.30 | 0.48 | 0.57 | |
Capex per Share |
(0.30) | (0.29) | (0.27) | (0.25) | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026